tbuckley/cabot-search huggingface dataset:
NIMG-39. CYTOSTATIC AGENTS COMBINED WITH TUMOR TREATING FIELDS (TTFIELDS) IN GLIOMA CELL LINES
Authors: Morris Groves, Rosa Schneiderman, Einav Zeevi, Tali Voloshin, Moshe Giladi, Eilon Kirson, Uri Weinberg
Journal: Neuro-Oncology (2016)

TTFields are low-intensity intermediate frequency alternating electric fields that disrupt mitosis. This innovative treatment approach is approved for the treatment of patients with recurrent glioblastoma and a recent phase 3 study demonstrated superior progression free and overall survival in patients with newly diagnosed glioblastoma when TTFields were added to standard of care. The goal of this study was to determine possible additive or synergistic effects of TTFields in combination with different cytostatic agents that were chosen based on their known pre-clinical anti-glioma activity, oral administration, safety, and cost. For in vitro studies, U-118 MG and U-87 MG glioma cells were treated with TTFields. To assess whether adding Mefloquine, Metformin, Bumetanide, Minocycline, or Ganciclovir to TTFields affects the responsiveness of glioma cancer cells, we treated the cells with these agents alone and in combination with TTFields. The surviving fractions were determined using cell counts. Invasion assays were performed using modified Matrigel-coated Boyden chamber. Our results demonstrate that in vitro application of TTFields led to a significant reduction in cell counts as compared to untreated cells in both cell lines. Further reduction in the number of cells was achieved when TTFields were combined with Mefloquine, Metformin, or Ganciclovir. Combination of TTFields and Minocycline did not show enhanced efficacy in the tested cell line. The combined treatment of TTFields and Bumetanide, an agent that is known to inhibit cellular motility, did not lead to reduction in cell counts but resulted in significant inhibition of glioma cells invasion as compared to each treatment alone. These results suggest that TTFields in combinations with the tested cytostatic agents lead to enhanced inhibitory effect on glioma cells and could positively impact treatment outcome.
Targeting Aminopeptidases by Tosedostat (TST) (CHR2797), Alone and with LBH589, Induces Significant Cytotoxicity Against Human Multiple Myeloma (MM) Cells
Authors: Chirag Acharya, Mike Y Zhong, Daniel Tannenbaum, Michelle Chen, Matt Ma, Jack Singer, Kenneth C. Anderson, Paul G. Richardson, Yu-Tzu Tai
Journal: Blood (2012)
Discontinuation of Nilotinib in Patients with Chronic Myeloid Leukemia Who Have Maintained Deep Molecular Responses for at Least 2 Years: A Multicenter Phase 2 Stop Nilotinib (Nilst) Trial
Authors: Norimitsu Kadowaki, Tatsuya Kawaguchi, Junya Kuroda, Hirohisa Nakamae, Itaru Matsumura, Toshihiro Miyamoto, Jun Ishikawa, Koji Nagafuji, Yutaka Imamura, Hirohito Yamazaki, Mototsugu Shimokawa, Koichi Akashi, Yuzuru Kanakura
Journal: Blood (2016)
Phase II study of everolimus (EVL) and octreotide (OCT) LAR in patients with non-functioning gastrointestinal neuroendocrine tumours (GI-NETs): EVERLAR study
Authors: J. Capdevila, A. Teulé, J. Barriuso, D. Castellano, C. Lopez, J.L. Manzano, V. Alonso, R. Garcia-Carbonero, E. Dotor, I. Matos, A. Custodio, O. Casanovas, R. Salazar
Journal: Annals of Oncology (2016)
Current Graft-Versus-Host Disease (GVHD), Relapse-Free Survival - a Novel, Dynamic Composite Endpoint to Better Define Effectiveness Following Allogenic Hematopoietic Cell Transplantation
Authors: Scott R. Solomon, Connie Sizemore, Michelle Ridgeway, Xu Zhang, Melhem Solh, Lawrence E. Morris, H. Kent Holland, Asad Bashey
Journal: Blood (2016)
Runmatic for running mechanics assessment (mobile app user guide)
Authors: Saúl M Rodríguez
Journal: British Journal of Sports Medicine (2017)

Runmatic 

Sports

iOS 9 or later; optimised for devices with slow-motion cameras, that is, iPhone 5s, iPhone 6/Plus, iPhone 6s/Plus, iPhone SE, iPhone 7/Plus, iPad mini 4, iPad Air 2 and iPad Pro. Compatible with any iOS device with iOS 9 or later.

$A14.99

Current version is V.3.1.3 which has support to any iPhone, iPad and iPod Touch with iOS 9 or later installed. No trial version is available.

The assessment of running mechanics is an important measure in the sports performance and clinical fields.1  Runmatic is a low-cost, easy-to-use smartphone app which integrates with the in-built video camera to obtain contact and flight times as primary outcomes (figure 1). Secondary outcomes, which are calculated from primary outcomes, integrate the vertical oscillation, leg stiffness, …
Breast cancer prognosis after neoadjuvant chemotherapy for breast cancers: molecular downstaging, proliferation, and endocrine sensitivity importance
Authors: M.-A. Benderra, S. Richard, M. Antoine, D. Buob, S. Zilberman, A. Esteso, J.P. Lotz, K. Kerrou, J. Gligorov
Journal: Annals of Oncology (2016)
Predictors of Clinical Outcome to Pentostatin, Cyclophosphamide and Rituximab (PCR) Followed by Campath for Relapsed/Refractory CLL – A Study of the Eastern Cooperative Oncology Group, E2903.
Authors: Neil E. Kay, Haesook T Kim, Sanford Kempin, Charla Secreto, Traci Knox, Renee Tschumper, Diane F Jelinek, Stephanie Smoley, Daniel VanDyke, Joel Saltzman, Steven T. Rosen, Brad Kahl, Martin S. Tallman
Journal: Blood (2008)
EXTH-14. ADD ON EFFECT OF EXISTING DRUGS TO TMZ FOR GLIOMA TREATMENT
Authors: Zhong-ping Chen
Journal: Neuro-Oncology (2016)

Temozolomide has been currently used as first line chemotherapy agent for GBM, and the best 5-year survival rate is only 9.8%. For searching methods to enhance antitumor efficacy of TMZ, several agents that are not antitumor medications have been tested. Interferons (IFNs), an immonomodulatory agent, are capable of sensitizing GBM to TMZ via multiple mechanism. Our in vitro and in vivo study has revealed that IFNα/β can enhance the cytotoxicity of TMZ, which are correlated with the down regulation of NF- κB and MGMT expression. Recent studies suggested that tumor cytotoxicity and radiosensitivity associated with histone deacetylases (HDACs). VPA (2-propylpentanoic acid) is one of the most interesting HDAC inhibitors. Recently, findings that VPA can induce hyperacetylation of histones means it is a possible agent that can enhance tumor cytotoxicity and radiosensitivity. We have found that VPA possess mild antitumor activity, may induce apoptosis (mild) as well as autophagy in glioma cell lines, and can increase antitumor activity of TMZ which could be related to enhancing autophagy. We investigated the anti-glioma efficacy of dihydroartemisinin (DHA) and combined with temozolomide (TMZ) on human glioma cell lines in vitro and in vivo. Our data suggest that DHA can inhibit proliferation of glioma cell lines and increase antitumor efficacy of TMZ, and possibly through inducing autophagy. We have tested and found that Beta-elemene (β-ELE) could compensate for TMZ to kill both glioma stem-like cells (GSLCs) and non-stem like cancer cells. Notch1 might be a downstream target of β-ELE. In conclusion, repurposing existing drugs which are not antitumor agents could be one of the permission ways for glioma treatment.
Diagnostic Complications of Thalassemic Hb Showa-Yakushiji (β110[G12] Leu→Pro),Observed in An African American Child with Co-Inherited Hb B2 (δ16[A13]Gly→Arg) and α-Thal-2 (-α3.7 deletion): Effects of Triple Globin Gene Abnormality On Phenotype.
Authors: Chinwe Obiaga, Niren Patel, Hernan Sabio, Natalia Dixon, Steffen E. Meiler, Lina Zhuang, Abdullah Kutlar, Ferdane Kutlar
Journal: Blood (2009)
TMOD-13. SIMULATING PATTERNS OF RECURRENCE FOLLOWING ISCHEMIA IN BRAIN TUMORS
Authors: Lee Curtin, Andrea Hawkins-Daarud, Alyx Porter, Joshua Jacobs, Markus Owen, Kristoffer van der Zee, Rami Aoun, Bernard Bendok, Kristin Swanson
Journal: Neuro-Oncology (2016)

Glioblastoma Multiforme (GBM) is the most aggressive primary brain tumor with median survival of 14 months from diagnosis. Following resection, GBM recurrence most often occurs locally but can recur distally. Experimentally, hypoxia has been seen to drive infiltrative growth of glioma cells, but its clinical effects are not well understood. However, a recent paper demonstrated that GBM patients with perioperative ischemia are more likely to recur distally than those without, 61% vs 19%. While this is convincing evidence that hypoxia is involved in generating distant recurrences, it does not fully answer the question regarding the difference between tumors that do or do not recur distally. We hypothesize that individual tumor growth kinetics may provide another part of the answer to this question. To investigate this question we utilized a previously developed spatio-temporal bio-mathematical model for glioma proliferation and invasion that encapsulates the complex interactions between tumor tissue and vasculature. We simulated multiple tumors defined by their growth kinetics as well as differing extents of perioperative ischemia. The model suggests a distal recurrence will occur following perioperative ischemia if a large enough proportion of the remaining tumor cells become hypoxic as they migrate through the ischemic region. Hypoxic cells favor migration to proliferation, supporting the hypothesis that they migrate across ischemic regions without being detected. Once cells migrate to regions with healthy vasculature, they are able to return to a normoxic phenotype and proliferate to an imageable density - thus appearing as a distal recurrence. We found that the tumor growth kinetics giving rise to diffuse tumors were the ones that recurred distally, but that nodular tumors were more likely to recur locally even in the presence of ischemia.
Effect of body mass index (BMI) on response to neoadjuvant therapy in human epidermal growth factor receptor 2 (HER2) positive breast cancer (BC): Analysis from NeoALLTO trial
Authors: G. Galli, I. Bradbury, S. Cinieri, D. Agbor-Tarh, F.G.M. De Braud, J. Baselga, J. Huober, D. Fumagalli, S. Sarp, M. Piccart, E. de Azambuja, S. Di Cosimo
Journal: Annals of Oncology (2016)
Survival impact of treatment for chronic obstructive pulmonary disease in patients with advanced non-small cell lung cancer
Authors: H. Ajimizu, H. Ozasa, S. Sato, Y. Sakamori, T. Funazo, Y. Yasuda, T. Nomizo, T. Tsuji, H. Yoshida, Y. Yagi, H. Nagai, A. Sato, M. Tsuchiya, S. Muro, Y. Nagasaka, M. Mishima, Y.H. Kim
Journal: Annals of Oncology (2016)
MR quantification of abnormal stromal enhancement in the periphery of invasive breast tumors
Authors: N. Nabavizadeh, C. Klifa, D. Newitt, Y. Lu, J. Hattangadi, C. Fisher, N. Hylton, C. Park
Journal: Journal of Clinical Oncology (2009)

636 Background: In dynamic contrast-enhanced MRI (DCEMRI), properties of tissue microvasculature and overall vascularity can be quantified using kinetics of contrast enhancement. It has been shown that areas with high signal enhancement ratio (SER) were significantly correlated with high tumor vascularity, and that mean SER in nearby non-cancerous breast stroma was significantly associated with disease free survival. No universally accepted methods exist to determine the optimal extent of histologically normal breast tissue to treat. Although a relationship between normal tissue SER and recurrence has been observed, the spatial relationship of enhancement within the non-cancerous stroma with respect to proximity of the tumor has not been shown. We hypothesized that abnormalities in vasculature exist within the histologically normal breast stroma that can be detected by measuring changes in enhancement intensity. Methods: We performed a secondary analysis of pre-treatment DCEMRI data from 27 invasive breast cancer patients. An automated, user-independent program was used to segment breast tissue from all other structures. A SER threshold was set to identify invasive tumor regions, and a tumor proximity map was generated giving the 3D distance of each normal breast tissue voxel to the nearest tumor voxel. A percent enhancement (PE) map was calculated for the normal stroma using the signal intensity change between the pre-contrast and post-contrast images. The proximity and PE maps were then combined to measure breast tissue enhancement at various distances from the tumor. Results: PE levels in normal breast tissue situated within 2 cm of the tumor region were significantly higher than at all more distant regions. Pairwise comparisons with Turkey's adjusted p-values indicated that the mean PE at 0 cm-1 cm is significantly higher than all other distant levels (p = &lt; 0.0001) and the mean PE at 1 cm-2 cm is significantly higher than 5 cm-6 cm (p = 0.006). Conclusions: Here, we show that the normal-appearing breast stroma within 0 cm to 2 cm of a primary tumor exhibits higher enhancement levels than stroma located far from the tumor. These results suggest that tissue surrounding the tumor region may contain tumor-related angiogenesis. These findings could help personalize surgery and radiation techniques. No significant financial relationships to disclose.
G PROTEIN COUPLED RECEPTORS MEDIATE FIBROBLAST CHEMOTAXIS INDUCED BY BRONCOALVEOLAR LAVAGE FLUID OF ARDS PATIENTS
Authors: V. Fanelli, V. Puntorieri, P. Cappello, P. Terragni, M. Bosco, L. Del Sorbo, E. L. Martin, L. Delsedime, L. Mascia, V. M. Ranieri
Journal: Intensive Care Medicine (2008)
Changes in Extrahepatic Iron Load in Response to Iron Chelation Versus Phlebotomy: Observations from the Twitch Trial
Authors: John C Wood, Alvarez Ofelia, Matthew M Heeney, Alex George, Cynthia Gauger, Beng Fuh, Stephen C Nelson, Carla W Roberts, Melissa Rhodes, Jamie Coleman, Russell E. Ware
Journal: Blood (2016)
Pleiotrophin Is Highly Produced by Myeloma and Breast Cancer and Transdifferentiates Human Monocytes into Endothelial Cells That Are Incorporated into Tumoral Blood Vessels.
Authors: Haiming Chen, Richard A. Campbell, Mingjie Li, Melinda S. Gordon, Dror Shalitin, Cathy S. Wang, Ariana M. Berenson, Jennifer Li, Hetty Wong, Benjamin Bonavida, James R. Berenson
Journal: Blood (2006)
ATIM-09. SUCCESSFUL EXPERIENCE WITH CLINICAL TRIALS FOR HIGH GRADE GLIOMA IN A COMMUNITY SETTING
Authors: Lars Anker, Lavinia Dobrea, Joy Nakhla, Viorela Pop, Lawrence Wagman
Journal: Neuro-Oncology (2016)

The majority of cancer patients in America are treated in community hospitals and prefer to be treated within a familiar setting, yet most clinical trials are conducted at university medical centers. This report demonstrates that clinical trials for brain tumors can be successfully carried out at a comprehensive community cancer center. Our multidisciplinary neuro-oncology program was established in 2010. All high grade glioma patients are discussed at treatment conferences and considered for clinical trials. Patients have access to studies in partnership with NCI cooperative groups, industry sponsored and investigator initiated trials. To facilitate further research, biospecimens from clinical trial participants are acquired within our tissue bank. Nationally, 20% of adults with cancer qualify for a clinical trial, yet only 3–5% consent. Over the last 4 years, we evaluated 58 patients for 8 different high grade glioma treatment trials, with 50% consenting (29/58). Of 19 patients who received at least one dose of study agent, 79% (15/19) completed treatment. Nationally, 30% of patients drop out of a clinical trial, whereas our voluntary withdrawal rate was only 3%. We had a 100% success rate in harvesting specimens for an autologous vaccine trial (DCVax®-L). Upcoming trials include an anti-angiogenic adenoviral vector (GLOBE), a purified retroviral replicating vector (TOCA5), and radiosurgery combined with tumor treatment field (TTF) therapy (METIS). Our experience demonstrates that clinical trials can successfully be carried out in a comprehensive community cancer center. Acquisition of complex neuro-oncology trials, high patient enrollment and retention, effective study management and reporting of quality data indicate our strong overall trial performance. Therefore, research centers in community hospitals can contribute their patient population to the success of multicenter clinical trials. Our patients are retained and enroll locally with minimal financial and travel burden, maintaining personalized care from their existing medical team.
NIMG-09. PREDICTION OF FACIAL NERVE POSITION IN LARGE VESTIBULAR SCHWANNOMA USING DIFFUSION TENSOR IMAGING TRACTOGRAPHY AND ITS INTRA-OPERATIVE CORRELATION
Authors: Sachin Borkar
Journal: Neuro-Oncology (2016)

Resection of large vestibular schwannomas (VS), can be associated with postoperative facial nerve injury. Diffusion-based tractography has emerged as a powerful tool for three- dimensional imaging and reconstruction of white matter ﬁbers; however, tractography of the cranial nerves has not been well studied. In this prospective study, we aim to predict the position of facial nerve in large vestibular schwannomas (> 3cm) using Diffusion Tensor Imaging (DTI) tractography and correlate it with intra-operative finding of the position of facial nerve. Twenty patients with large vestibular schwannomas (>3cm) undergoing surgery were subjected to preoperative DTI imaging to predict the position of facial nerve in relation to the tumor. The surgeon was blinded to the results of the preoperative DTI tractography. A comparative analysis was then made during operation. The location of the facial nerve in relation to the tumor was recorded during surgery using facial nerve stimulator. Out of the twenty patients who underwent DTI tractography, it was not possible to preoperatively identify facial nerve in one patient. In another patient, although DTI tractography predicted the position of facial nerve, it was not identified intraoperatively. Out of the remaining 18 patients, DTI tractography predicted facial nerve position was in sync with intraoperative facial nerve position in 16 patients (89 % concordance). It was discordant in two patients (11%), but this was not found to be statistically significant (p value -0.3679). This study validates the reliability of facial nerve diffusion tensor (DT) imaging–based fiber tracking for prediction of facial nerve position in patients with large vestibular schwannomas. The reliable preoperative visualization of facial nerve location in relation to VS would allow surgeons to plan tumor removal accordingly and may increase the safety of surgery.
Potentially druggable molecular and immune-related pathways drive the prognosis of resected squamous cell lung carcinoma (R-SqCLC): preliminary results of prognostic outliers according to a clinicopathological model
Authors: S. Pilotto, M. Simbolo, I. Sperduti, S. Novello, C. Vicentini, U. Peretti, S. Pedron, M. Milella, A. Mafficini, P. Visca, M. Volante, F. Facciolo, A. Santo, M. Infante, L. Carbognin, M. Brunelli, M. Chilosi, A. Scarpa, G. Tortora, E. Bria
Journal: Annals of Oncology (2016)
Long-term duration of axitinib treatment in advanced renal cell carcinoma
Authors: B.I. Rini, V. Grünwald, E. Jonasch, M.N. Fishman, Y. Tomita, M.D. Michaelson, J. Tarazi, L. Cisar, A.H. Blair, B. Rosbrook, T. Hutson
Journal: Annals of Oncology (2016)
The role of interim FDG-PET after induction chemotherapy as a prediction of the efficacy of concurrent chemoradiotherapy in locally advanced squamous carcinoma of the head and neck
Authors: K.-R. Kim, H.-J. Shim, J.-E. Hwang, S.-H. Cho, I.-J. Chung, S.Y. Kwon, W.-K. Bae
Journal: Annals of Oncology (2016)
EXTH-39. PRECLINICAL TESTING OF DIETARY HISTONE DEACETYLASE INHIBITORS ON FRESH FIG-ROS1 POSITIVE HUMAN GLIOBLASTOMA TISSUE IN EX-VIVO MODELS
Authors: Arabinda Das, Stephen Lowe, William Alexander Vandergrift, Naren L Banik, Michele L Decandio, Bruce M Frankel, Jeffrey Raizer, Libby Kosnik Infinger, Abhay K. Varma, Sunil J. Patel, Scott M. Lindhorst, David Cachia
Journal: Neuro-Oncology (2016)

Experimental evidence has shown the primary reason for treatment failure in glioblastoma (GBM) is signal redundancy due to co-activation of several functionally linked receptor tyrosine kinases (RTKs), oncogenic c-ros oncogene1 (ROS1: RTK class orphan) fusion kinase FIG (fused in GBM)-ROS1 and also histone dacetylase (HDAC) activity. Therefore, targeting these functionally linked kinases and HDACs could be useful for GBM therapy. The study consisted of 10 tissue samples from 10 patients who underwent neurosurgical resection of GBM at the Medical University of South Carolina. We established GBM slice cultures (obtained from GBM patients), which can be kept in vitro for at least 10 days. Upon treatment with dietary HDAC inhibitors such as Alliin, Allicin, dially disulfite (DATS), methyl allyl trisulfide (MATS), L-Deoxyalliin (S-allyl cysteine), S-methyl L-cysteine), slices were collected for biochemical analysis. Our ex vivo models demonstrated that 72 hr treatments with 25 µM of 6 HDAC inhibitors induce antitumor activity on FIG-ROS1-positive and elevated levels of lysine 9-acetylated histone H3 GBM cells. Our western blot and activity assay results also demonstrate that combination blockade of HDAC activity and expression of FIG, p-ROS1, p-ALK, and p-Met protein levels augment apoptosis in ex vivo FIG-ROS1+ GBM slices obtained from GBM patients, which mechanistically involves activation of caspase-3. Interestingly, it is important to note that we did not see significant effect of HDAC inhibitors on FIG-ROS1-negative GB cells. Administration of HDAC inhibitors induce antitumor activity in FIG-ROS1-positive GBM cells in an ex-vivo model. Further studies in different animal models of are warranted to determine useful therapies for the management of human GBMs.
Relation of Milk Influence to Mammary Tumors of Hybrid Mice
Authors: Howard B. Andervont
Journal: JNCI Journal of the National Cancer Institute (1945)

Journal Article Relation of Milk Influence to Mammary Tumors of Hybrid Mice Get access Howard B. Andervont Howard B. Andervont Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 5, Issue 6, June 1945, Pages 391–395, https://doi.org/10.1093/jnci/5.6.391 Published: 01 June 1945
Doctors can withhold treatment from baby, judge rules
Authors: Clare Dyer
Journal: BMJ (2017)

Doctors at Great Ormond Street children’s hospital in London will be acting lawfully if they withhold aggressive and invasive treatment from an eight month old baby with only weeks to live, a High Court judge has ruled.

The parents of the baby girl, who was born with hypoplastic left heart syndrome, want her to have “any procedure possible if that would prolong her life for one day,” said Ms Justice Russell.

But treatment such as cardiopulmonary resuscitation, intubation and mechanical ventilation, central venous lines, and further chest drains “are unlikely to succeed and will only cause elemental pain and distress for …
Blocking Protein S Improves Hemostasis in Hemophilia a and B
Authors: Luca Bologna, Raja Prince, Mirko Manetti, Daniela Melchiorre, Irene Rosa, Natacha Dewarrat, Poorya Amini, Jose A Fernandez, Claudia Quarroz, Yasuhiro Matsumura, Johanna A Kremer Hovinga, Shida Yousefi, John H. Griffin, Simon Hans-Uwe, Lidia Ibba Manneschi, Francois Saller, Sara Calzavarini, Anne Angelillo-Scherrer
Journal: Blood (2016)
Discussion of Structure-Reactivity Relationships of Halo-Ether Carcinogenicity: Reply
Authors: Richard F. Merritt
Journal: JNCI Journal of the National Cancer Institute (1973)

Journal Article Discussion of Structure-Reactivity Relationships of Halo-Ether Carcinogenicity: Reply Get access Richard F. Merritt Richard F. Merritt Rohm and Haas Company, Philadelphia, Pennsylvania Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 50, Issue 5, May 1973, Page 1412, https://doi.org/10.1093/jnci/50.5.1412 Published: 01 May 1973
A Phase 2 Study of High-Dose Melphalan Plus Bortezomib (Mel/Vel) Conditioning Followed By Autologous Hematopoietic Cell Transplantation in Myeloma
Authors: Taiga Nishihori, Jose L Ochoa-Bayona, Rachid Baz, Kenneth H. Shain, Christine Simonelli, Chiaka Nwoga, Ryan Hillgruber, Daniel Sullivan, Claudio Anasetti, Melissa Alsina
Journal: Blood (2014)